> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Woodcock Joins Friends of Cancer Research Board
- URL: https://www.fdaweb.com/woodcock-joins-friends-of-cancer-research-board/
- Published: 2025-01-22T12:00:00.000Z
- Updated: 2026-09-14T14:51:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158525

Patient advocacy group Friends of Cancer Research has added former principal deputy commissioner **Janet Woodcock** to its board of directors. Woodcock retired late 2023 after 37 years at the agency ([see earlier story](https://www.fdaweb.com/janet-woodcock-retiring-in-early-2024/)). She spent over two decades as CDER director until the Covid-19 pandemic saw her move to the government’s “Operation Warp Speed” response in early 2020\. In this capacity, she supported the development, evaluation, and availability of treatments such as monoclonal antibodies and antiviral drugs for patients with Covid-19.

 The group also added Kendall Square Policy Strategies principal **Paul Kim** to the board. Previously, Kim was head of the FDA and federal government strategies practices at Foley Hoag for 20 years. Earlier in his career, Kim served as counsel to the late Senator **Edward Kennedy** (D-MA).